Merck KGaA (FRA:MRK) has been given a €84.00 ($103.70) target price by investment analysts at Nord/LB in a research note issued on Monday. The firm presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s target price suggests a potential upside of 5.93% from the company’s current price.
Several other research analysts have also recently weighed in on the stock. UBS Group restated a “buy” rating on shares of Merck KGaA in a research report on Monday, January 15th. JPMorgan Chase & Co. set a €100.00 ($123.46) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, December 12th. Kepler Capital Markets set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the stock a “buy” rating in a report on Wednesday, January 17th. Sanford C. Bernstein set a €115.00 ($141.98) target price on shares of Merck KGaA and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, Berenberg Bank set a €116.00 ($143.21) price target on shares of Merck KGaA and gave the company a “buy” rating in a report on Thursday, November 23rd. Twelve analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of €102.00 ($125.93).
Merck KGaA (FRA:MRK) traded up €1.04 ($1.28) during mid-day trading on Monday, reaching €79.30 ($97.90). 1,605 shares of the company traded hands. Merck KGaA has a 1 year low of €76.60 ($94.57) and a 1 year high of €115.00 ($141.98). The company has a market cap of $10,280.00 and a PE ratio of 13.26.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.